T0	Outcomes 895 965	percentages of CD3+, CD4+, CD56+, CD3+CD56+ cells, and CD4+/CD8+ ratio
T1	Outcomes 1152 1175	percentage of CD8 cells
T2	Outcomes 1232 1287	1-year and 18-month recurrence rates of the study group